This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (111)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Deepak L. Bhatt, MD; Eric J. Topol, MD

JAMA. 2000;284:1549-1558.

Context  The central role of platelet-rich thrombus in the pathogenesis of acute coronary syndromes (ACSs) is well-known. Glycoprotein IIb/IIIa (Gp IIb/IIIa) receptor antagonists are potent inhibitors of platelet function that may be expected to affect favorably the natural history of ACSs.

Objective  To define the optimal role of Gp IIb/IIIa inhibitors in treatment strategies for ACSs.

Data Sources  A MEDLINE search was performed to identify all English-language articles regarding use of Gp IIb/IIIa inhibitors in ACSs published between 1966 and June 2000. In addition, relevant abstracts from the annual meetings of the American Heart Association, American College of Cardiology, and the European Society of Cardiology were reviewed.

Study Selection  Only studies of 500 or more patients were included. Of 15 studies identified, 10 randomized, placebo-controlled, double-blind trials of Gp IIb/IIIa inhibitors in ACSs were selected for review.

Data Extraction  Data quality was determined by publication in the peer-reviewed literature or presentation at an official cardiology society–sponsored meeting, as well as by verification with the primary author.

Data Synthesis  Three members of this class of drugs are available for intravenous use. Abciximab, eptifibatide, and tirofiban hydrochloride, each have data demonstrating their value in improving the outcomes of patients presenting with ACSs. Current evidence supports use of these drugs in both conservative and invasive treatment strategies. Glycoprotein IIb/IIIa–blocking therapy is safe, and with proper precautions, bleeding risks can be minimized. Biological differences exist among these agents, but as of yet, no head-to-head comparisons have been made of their clinical efficacy. Unlike intravenous Gp IIb/IIIa inhibitors, available data regarding any role of oral Gp IIb/IIIa inhibitors are not favorable.

Conclusion  Current data indicate that intravenous Gp IIb/IIIa inhibitor therapy merits a prominent role in the initial management of patients with ACSs.

Author Affiliation: Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio.

RELATED ARTICLE

September 27, 2000
JAMA. 2000;284(12):1587-1588.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis
Bhatt
NEJM 2007;357:2078-2081.
FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:652-726.
FULL TEXT  

Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Meadows and Bhatt
Circ. Res. 2007;100:1261-1275.
ABSTRACT | FULL TEXT  

Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease
Aronow
J. Gerontol. A Biol. Sci. Med. Sci. 2007;62:518-524.
ABSTRACT | FULL TEXT  

Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups
Hernandez et al.
Heart 2007;93:450-455.
ABSTRACT | FULL TEXT  

Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight)
Dudek et al.
Eur Heart J Suppl 2007;9:A25-A31.
ABSTRACT | FULL TEXT  

Activation of Platelet Function Through G Protein-Coupled Receptors
Offermanns
Circ. Res. 2006;99:1293-1304.
ABSTRACT | FULL TEXT  

Shifting the Diagnosis of Periprocedural Myocardial Infarction Upstream
Bhatt
Circulation 2006;114:1898-1900.
FULL TEXT  

Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial
Kastrati et al.
JAMA 2006;295:1531-1538.
ABSTRACT | FULL TEXT  

To Cath or Not to Cath: That Is No Longer the Question
Bhatt
JAMA 2005;293:2935-2937.
FULL TEXT  

Transfer for Primary Angioplasty: The Importance of Time
Herrmann
Circulation 2005;111:718-720.
FULL TEXT  

Utilization of Early Invasive Management Strategies for High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative
Bhatt et al.
JAMA 2004;292:2096-2104.
ABSTRACT | FULL TEXT  

Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions
Goto et al.
J Am Coll Cardiol 2004;44:316-323.
ABSTRACT | FULL TEXT  

Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?
Aukrust et al.
J Am Coll Cardiol 2004;43:2326-2328.
FULL TEXT  

New anticoagulants and antiplatelet agents
Shore-Lesserson
Canadian J. Anesthesia 2004;51:R9-R9.
FULL TEXT  

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin
Reiter et al.
Blood 2003;102:4594-4599.
ABSTRACT | FULL TEXT  

Composite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty?
Freemantle et al.
JAMA 2003;289:2554-2559.
ABSTRACT | FULL TEXT  

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction: The TACIP Study: A Randomized, Double-Blind, Multicenter Trial * Can Aspirin Ever Be Surpassed for Stroke Prevention?
Matias-Guiu et al.
Stroke 2003;34:840-848.
ABSTRACT | FULL TEXT  

Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation
Nannizzi-Alaimo et al.
Circulation 2003;107:1123-1128.
ABSTRACT | FULL TEXT  

Thrombocytopenia in Critical Care Patients
DeLoughery
J Intensive Care Med 2002;17:267-282.
ABSTRACT  

D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease
Komarov et al.
Eur Heart J 2002;23:1309-1316.
ABSTRACT  

Involvement of Glycoprotein VI in Platelet Thrombus Formation on Both Collagen and von Willebrand Factor Surfaces Under Flow Conditions
Goto et al.
Circulation 2002;106:266-272.
ABSTRACT | FULL TEXT  

Eptifibatide and 7E3, but Not Tirofiban, Inhibit {alpha}v{beta}3 Integrin-Mediated Binding of Smooth Muscle Cells to Thrombospondin and Prothrombin Response
Scarborough et al.
Circulation 2002;105 :e46-e46.
FULL TEXT  

Treatment of Acute Coronary Syndromes
Owen et al.
NEJM 2002;346:206-208.
FULL TEXT  

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Collaboration
BMJ 2002;324:71-86.
ABSTRACT | FULL TEXT  

Pharmacologic preservation of the hemostatic system during cardiac surgery
Levy
Ann. Thorac. Surg. 2001;72:S1814-1820.
ABSTRACT | FULL TEXT  

Ninety-Minute Exclusion of Acute Myocardial Infarction By Use of Quantitative Point-of-Care Testing of Myoglobin and Troponin I
McCord et al.
Circulation 2001;104:1483-1488.
ABSTRACT | FULL TEXT  

Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation
Frelinger et al.
Circulation 2001;104:1374-1379.
ABSTRACT | FULL TEXT  

Management of Acute Coronary Syndromes
SCHULMAN and FESSLER
Am. J. Respir. Crit. Care Med. 2001;164:917-922.
FULL TEXT  

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization
Topol et al.
NEJM 2001;344:1888-1894.
ABSTRACT | FULL TEXT  

Future Trials of Antiplatelet Agents in Cardiac Ischemia
Throckmorton
NEJM 2001;344:1937-1939.
FULL TEXT  

National Institute for Clinical Excellence guidance: too NICE to glycoprotein IIb/IIIa inhibitors?
KNIGHT
Heart 2001;85:481-483.
FULL TEXT  

Additional articles abstracted in ACP Journal Club
Evid. Based Med. 2001;6:35-35.
FULL TEXT  

Chemokines on the Rise : MCP-1 and Restenosis
Schmidt and Stern
Arterioscler. Thromb. Vasc. Bio. 2001;21:297-299.
FULL TEXT  

Glycoprotein Inhibitors and Fibrinolysis in Myocardial Infarction
Ring et al.
JAMA 2000;284:3124-3125.
FULL TEXT